Oncogenic viruses like human papilloma virus (HPV) or Epstein Barr virus (EBV) are a major cause of human 2 cancer. Viral oncogenesis has a direct impact on treatment decisions because virus-associated tumors can 3 demand a lower intensity of chemotherapy and radiation or can be more susceptible to immune check-4 point inhibition. However, molecular tests for HPV and EBV are not ubiquitously available. 5
Introduction 19
Oncogenic viruses cause approximately 15% of malignant tumors in humans. 1 Viruses can induce cancers 20 with different histology and across different anatomic sites including squamous cell carcinomas (e.g. head 21 and neck, cervix), adenocarcinomas (e.g. gastric), sarcomas (e.g. Kaposi), lymphomas (e.g. Burkitt) and 22 hepatocellular carcinoma. Virus-driven tumors are an important health issue in western countries, but 23 their global health impact is even higher as 80% of all virus-driven cancers occur in developing nations. 2 
24
Their incidence is expected to increase drastically in the next decade in developing and economically de-25 veloped countries. 3, 4 Some types of cancer are almost always virally driven (e.g. cervical cancer) while 26 others can have viral or non-viral driver mechanisms (e.g. head and neck cancer or gastric cancer). In these 27 cases, it is important to determine if a patient's tumor has a viral origin because if this is the case, a dif-28 ferent clinical management may be warranted and virus status might influence the choice of a clinical trial 29 for that particular patient. For example, in the case of head and neck squamous cell carcinoma (HNSC), 30 patients with human papilloma virus (HPV)-positive tumors have superior overall survival compared to 31 patients with HPV-negative tumors of the same stage and can benefit from treatment de-escalation. 5 
32
Likewise, patients with Epstein-Barr-Virus (EBV) related gastric adenocarcinoma tend to have a better 33 prognosis and EBV positivity has been suggested as a biomarker for immunotherapy response. 6 
34
The gold standard method for detection of viruses in human cancer is dependent on the tumor type. In 35 head and neck cancer, overexpression of p16 as assessed by immunohistochemistry is the most commonly 36 used surrogate marker for virus presence. However, p16 is neither perfectly sensitive nor specific 7 , and 37 some centers also use HPV polymerase-chain reaction, in-situ hybridization, or targeted DNA sequencing 38 for HPV detection in tumor tissue. While these tests are more specific, they are also more expensive and 39 time consuming. Presence of latent EBV infection in gastric cancer is usually measured using EBV-encoded 40 RNA in-situ hybridization in pathology samples, which has a relatively high sensitivity and specificity but 41 requires dedicated testing equipment and expertise for accurate interpretation. 42
In the present study, we hypothesized that morphological features correlating with the presence of vi-43 ruses in solid tumors can be deduced from hematoxylin and eosin (H&E) histology, which is routinely 44 available for almost any patient with a solid tumor. As a tool for feature extraction from images, we used 45 deep learning, a form of artificial intelligence (AI), which has previously been used to detect high-level 46 morphological features directly from histological images. 8-10 47 48
Methods

49
Ethics and data sources 50
All experiments were conducted in accordance with the Declaration of Helsinki and the International Eth-51 ical Guidelines for Biomedical Research Involving Human Subjects. Anonymized scanned whole slide im-52 ages were retrieved from The Cancer Genome Atlas (TCGA) project through the Genomics Data Commons 53 Portal (https://portal.gdc.cancer.gov/). From this source, we retrieved images of head and neck squamous 54 cell carcinoma (HNSC) 11 and gastric adenocarcinoma (stomach adenocarcinoma, STAD) 12 . Exclusion crite-55 ria for patients in these cohorts were missing values in virus status, corrupt image files or lack of tumor 56 tissue on the whole slide image. For TCGA-HNSC, images from N=450 patients were downloaded of which 57 N=38 met exclusion criteria, leaving images from N=412 patients for further processing. For TCGA-STAD, 58 images from N=416 patients were downloaded of which N=99 met exclusion criteria, leaving N=317 pa-59 tients for further processing. Furthermore, we retrieved anonymized archival tissue samples of N=105 60 patients with HNSC from the University of Chicago Medicine Pathology archive (Chicago, Illinois, USA; 61 "UCH-HNSC") and anonymized tissue samples of N=197 patients with gastric cancer from the Kanagawa 62 Cancer Center Hospital (Yokohama, Japan; "KCCH-STAD") as described before 13 . For HNSC, HPV status was 63 determined as described by Campbell et al. 14 (by consensus of DNA sequencing 15 and RNA sequencing 16 ). 64
For TCGA-STAD, EBV status was retrieved from genomic subtypes as described by Liu et al. 17 . For samples 65 in UCH-HNSC, HPV status was defined by polymerase-chain reaction for the viral genes E6 and E7. For 66 tumor samples in KCCH-STAD, EBV status was defined by EBV-encoded RNA in-situ hybridization. 18 67
Deep transfer learning workflow 68
All histological slides were reviewed and tumor regions were manually delineated in QuPath 19 , tessellated 69 into tiles of 256 x 256 µm 2 which were subsequently downsampled to 224 x 224 px, yielding an effective 70 magnification of 1.14 µm/px. These tumor tiles were used for deep transfer learning in MATLAB R2019a 71 as described before 9,10 . We used a modified VGG19 deep convolutional neural network 20 which was pre-72 trained on ImageNet (http://www.image-net.org, architecture shown in Suppl. Table 1 ). VGG19 was cho-73 sen because of its previously proven performance in detecting multiple tissue components in human can-74 cer histology 9 and because of its compatibility with the Deep Dream method (see below). All TCGA cohorts 75 were randomly split into three equal subsets at patient level. A VGG19 classifier was trained on these data 76 in a three-fold cross-validated way. This procedure yielded three independent classifiers which were eval-77 uated on their respective test set of held-out patients. For each tumor type, the classifier was subse-78 quently re-trained on the whole TCGA set and evaluated on an external test set. 79
Feature visualization 80
To trace back deep-learning based predictions to human-understandable morphological patterns in his-81 tology, we used deep-dream-based visualization of output layer neurons for each class. We used a 82 Color optimization was done with identical parameters for all deep-dream-images generated by a given 87 network. 88
Statistics and data presentation 89
Classifier performance was assessed by the Area under the Receiver Operating Curve (AUC under the ROC) 90 with sensitivity (true positive rate, TPR) plotted on the vertical axis and 1 -specificity (false positive rate, 91 FPR) plotted on the horizontal axis. 95% confidence intervals for the AUC were calculated with 500-fold 92 bootstrapping with the "bias corrected and accelerated percentile method" 28 unless otherwise stated. 93
For three-fold cross validated experiments, the mean of AUCs and the mean of confidence interval 94 boundaries from all three classifiers is given if not otherwise noted. The ROC procedure is a widely used 95 technique to assess the power of a classifier for any possible cutoff value of a numerical test. In this study, 96 the cutoff for "percentage of virus-positive image tiles" was varied, yielding different sensitivity/specificity 97 pairs which are plotted as ROC curves. 98
Data availability 99
Images from the TCGA cohorts are available at https://portal.gdc.cancer.gov/. Our source codes are avail-100 able at https://github.com/jnkather/VirusFromHE. 101 102
Results
103
Deep learning detects virus presence in squamous cell carcinomas and adenocarcinomas 104
We hypothesized that the presence of human papillomavirus (HPV) can be detected in head and neck 105 squamous cell carcinoma (HNSC, Figure 1a ) and that the presence Epstein-Barr-Virus (EBV) can be de-106 tected in gastric adenocarcinoma (STAD, Figure 1b 
Noisy tile level data yields high patient-level accuracy in external validation cohorts 117
To assess the robustness of the classifiers, we used the neural network that was trained on the entire 118 TCGA patient cohorts for head and neck and gastric cancer, respectively, and evaluated the classifiers on 119 external validation cohorts. Non-overlapping tissue tiles of 256 µm edge length were used to predict a 120 "virus probability score" which classified each tile as either virus positive or negative (derived from a tu-121 mor that was virally induced or derived from a tumor that was non-virally induced). These predictions 122 were subsequently pooled on a patient level as "fraction of positive tiles" with varying thresholds accord-123 ing to the Receiver Operating Characteristic procedure (Figure 2a ). Because each tile in the training set 124 was assigned the label of the corresponding patient (obtained via bulk testing of tissue) and the tiles 125 contained a multitude of different tissue types (tumor epithelium, stroma, necrosis, mucus, and others), 126 this training set was inherently noisy. Correspondingly, predictions for virus-negative tiles in the EBV test-127 ing set were noisy with many false positive tile-level predictions (Figure 2b , right-hand side). However, 128 tiles from virus-positive patients were mostly classified correctly (Figure 2a This cohort had two main differences compared to the TCGA cohort which might negatively affect classi-139 fier performance: first, a polymerase-chain reaction for high-risk HPV viral genes was used to determine 140 virus status. Second, this cohort was artificially balanced for HPV status and thus had a much higher prev-141 alence of HPV-induced cancer than TCGA. In spite of these stark differences, our classifier achieved an 142 AUC of 0.70 [0.66; 0.74] for HPV prediction in UCH-HNSC. Manual review of representative tissue tiles by 143 an expert pathologist showed that tiles with a high HPV prediction score were "carcinomas with large 144 nested, broad-based invasion and relative decrease in cytoplasmic keratinization, resulting in a blue (cool-145 toned) appearance". This is compatible with previously known morphological features of HPV-positive 146 HNSC. 22 Tiles with a low HPV prediction score were "carcinomas with small nested invasion and eosino-147 philic (pink or warm-toned) cytoplasmic keratinization". Thus, we conclude that in HNSC as well as in 148 gastric cancer, predictions of viral status in individual tissue tiles by a deep neural network were plausible 149 to expert pathologists. 150
Together, these data show that despite noisy training data and tile-level misclassifications, patient-level 151 prediction of virus status in HNSC and gastric cancer can reach a high accuracy. 152
Reverse-engineering trained neural networks 153
Attempting to characterize more precisely which morphological features may have been used by the neu-154 ronal network to detect virus-induced cancer, we used a feature-visualization method and discussed the 155 results with a panel of expert pathologists. We hypothesized that reverse-engineering features from neu-156 ral networks could be used as a plausibility check for deep learning, completing the cycle "human to AI 157 and back". In an exploratory study, we employed the Deep Dream algorithm which uses a trained neural 158 network (Figure 3a) to create pseudo-images for each output class in the classification layer (Figure 3b ). 159
This approach yielded "pseudo-histology" images for HPV positive and negative HNSC (Figure 3b ) and EBV 160 positive and negative gastric cancer (Figure 3c ), discussing the resulting images with five pathologists. In 161 general, pathologists described the images as "beautiful" and "psychedelic". Relating the aspect of 162 pseudo-histology in histological terms, they described the features as "a sheet of small nodules composed 163 of bright, predominantly warm colors" (HPV negative HNSC, Figure 3c Together, these data show that deep learning can plausibly sort tissue tiles (Figure 2d ) and yields a high 170 classification performance for virus presence (Figure 2c ). The actual morphological patterns used for this 171 classification may be different from the ones that humans typically use but can be visualized in a way that 172 might be understandable for humans through the Deep Dream algorithm (as has been shown in non-173 medical applications 23 ). Based on this, we conclude that, to test for virus presence (such as sequencing) are costly, require a high level of expertise (such as in-situ 182 hybridization) and not all assays achieve a perfect classification accuracy (such as p16 immunohistochem-183 istry 24 ). Here, we present a deep-learning-based low-to-no-cost assay for routine detection of virus pres-184 ence from ubiquitously available histology in two major tumor types of very different histology. We 185 demonstrate that classification accuracy is as high as AUC 0.81 when trained with a few hundred patients. 186
Our approach relies on digitally scanned images of hematoxylin & eosin stained tissue slides. The cost to 187 scan such a histology slide is well below $10 at low throughput and considerably lower at high through-188 put 10 , potentially enabling noticeable cost savings for virus testing of tumor tissue in the future. 189
At the moment, sensitivity and specificity of our classifier is lower than in routine diagnostic tests: for EBV 190 detection in gastric cancer by EBV-encoded RNA in-situ hybridization, one study reported a sensitivity of 191 100% at a specificity of 90%. 25 For HPV detection in HNSC by p16 immunohistochemistry, another study 192 reported a sensitivity of 97.4% and a specificity 93.75%. 24 As shown in Figure 1e -f and Figure 2c , the deep 193 learning classifier approaches these gold standard methods but is still less sensitive and specific. However, 194 sensitivity and specificity of our method are higher than those in previous studies of deep-learning based 195 prediction of molecular features from histology. 8,26 196 In our experiments, the deep learning classifiers reached a high cross-validated performance which we 197 could replicate in an external validation set for gastric cancer (Figure 2c ). In the multicenter TCGA-HNSC 198 cohort, cross-validated HPV detection performance was high, but dropped in the external validation co-199 hort UCH-HNSC. This may be related to the relatively small patient size of this cohort or due to different 200 gold standards for HPV detection (consensus of DNA and RNA sequencing in TCGA-HNSC and polymerase-201 chain reaction in UCH-HNSC). Most probably, however, this is due to the very different prevalence of virus-202 induced cancers in the training set and in the test set. Whereas the training set (TCGA-HNSC) reflected 203 the natural prevalence of HPV-positive cancers, the test set (UCH-HNSC) was artificially balanced to a 204 prevalence of 50%. This may have negatively affected classifier performance as has been described for 205 mutation prediction in lung cancer 8 . 206 According to our experience from similar tasks, it can be expected that training on larger clinical cohorts 207 will likely improve performance of our method. Similarly, further optimizing hyperparameters and neural 208 network architectures will likely yield a performance boost. Also, further dividing deep learning classifiers 209 by anatomical sub-sites of tumors (e.g. oropharyngeal or hypopharyngeal) will likely increase perfor-210 mance. In the end, this image-based biomarker, like all biomarkers, needs to be tested in prospective 211 clinical trials before widespread clinical use. 212
A new aspect of our study is the approach "human to AI and back": humans (expert pathologists) deline-213 ated tumor tissue in whole slide sections and thus enabled the AI to detect virus presence in histological 214 images. In turn, using deep-dream-based feature visualization, we show that the AI can in principle inform 215 a human observer about morphological features of interest. Feature visualization by Deep Dream and 216 similar methods 27 is well-established to understand the inner workings of deep neural networks. Yet, to 217 our knowledge, this has never been systematically used for pathologist-AI-crosstalk. Thus, our study 218 shows for the first time that deep learning algorithms can not only be used as tools to facilitate diagnostic 219 routine but could also enable human observers to get a different viewpoint on histomorphology. 
